Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Pancreatic neuroendocrine tumours
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== '''Functional''' - 15-50% - ''only refers to those tumours associated with clinical symptoms'' === ==== '''Insulinoma''' (most common) ==== *** Summary **** Most common **** Typically small and benign - average size 1-1.5cm **** >99% found in pancreas - uniformly distributed throughout pancreas **** <10% are malignant **** Majority sporadic *** Presentation **** Age 40-45 **** Symptoms caused by hypoglycaemia - headaches, confusion, visual disturbances, or catecholamines causing palpitations, sweating, tremors **** '''Whipple's triad''' - symptoms of hypoglycaemia, BSL < 4, relief of symptoms with administration of glucose *** Diagnosis **** Elevated insulin to glucose ratio during fasting, with associated elevated levels of C-peptide **** Gold standard is a 48 hour fasting test, with levels every 6 hours **** Can be difficult to localise previously, but now fairly straightforward with EUS ***** Initial CT/MRI ***** Can try somatostatin receptor scan - but again often misses it ***** EUS positive in 70-95% of cases **** Distributed equally throughout the pancreas, and can occur in duodenum, splenic hilum, or gastrocolic ligament * Treatment ** Medical - small, frequent meals and control of hypoglycaemia ** Enucleation best surgery - cure 85-95% *** Can be done safely if tumour is 2-3mm from PD ** Pancreatic resection less common, generally unnecessary ** Operative exploration - can find it via palpation and USS 92% of the time *** Blind distal resection is not recommended if unable to find it ** ==== '''Gastrinoma''' (second most common) ==== ** See separate topic under UGIS ==== '''Glucagonoma''' (rare) ==== ** Presentation *** '4 D's' *** Dermatitis - necrolytic migratory erythema - primarily intertriginous locations like perineum, also trunk and legs *** Diabetes (usually mild) *** Depression *** DVT ** Diagnosis *** High glucagon (fasting level >1000pg/mL is diagnostic) *** CT/MRI to localise lesion *** Tend to be larger than other PNETs, mostly in body or tail ** Treatment *** Resect when possible *** Dermatitis resolves rapidly with treatment of hyperglycaemia *** No effective chemotherapy against metastatic disease, but they are slow-growing and don't often kill ==== '''VIPoma''' - vasoactive intestinal polypeptide-secreting tumour - rare ==== ** Presentation *** Verner-Morrison syndrome - watery diarrhoea, hypokalaemia, achlorhydria (WDHA) *** Excessive VIP inhibits gastric acid secretion, bone resorption and glycogenolysis and causes vasodilation, resulting in respective symptoms of hypochlorhydria, hypercalcaemia, hyperglycaemia, and flushing ** Diagnosis *** Serum VIP *** Majority are malignant, 70% have mets at diagnosis *** Generally visible on CT/MRI *** Somatostatin receptor scans generally work well for these ** Treatment *** Initially, fix the electrolytes and volume status - somatostatin analogues +/- glucocorticoids *** Resection *** Somatostatin analogues will give excellent symptomatic control with or without surgery ==== '''Somatostatinoma''' (rare) ==== ** Presentation *** Classically diabetes, diarrhoea or steatorrhoea, and weight loss as a result of the inhibitory effect of somatostatin ** Diagnosis *** Fasting plasma somatostatin level > 3 ULN *** If index of suspicion is high, but serum somatostatin level is normal, a stimulatory or inhibitory test can be performed ** Treatment *** Complete resection is ideal but often not possible *** Consider debulking, chemoembolisation of primary and metastatic tumours, and chemotherapy *** Octreotide is effective at suppressing symptoms ==== Other rare functional tumours (rare) ==== ** ACTH-producing ** Parathyroid hormone-related peptide
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Pancreatic neuroendocrine tumours
(section)
Add topic